Company Description
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.
The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.
It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system.
It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions.
The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally.
The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.
Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Jul 21, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | James Foster |
Contact Details
Address: Biocity Glasgow, Bo'ness Road, Newhouse Lanarkshire, X0 ML1 5UH United Kingdom | |
| Phone | 44 020 7788 7414 |
| Website | viraxbiolabs.com |
Stock Details
| Ticker Symbol | VRAX |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001885827 |
| CUSIP Number | G9495L109 |
| ISIN Number | KYG9495L1251 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| James Foster | Chairman and Chief Executive Officer |
| Jason D. Davis | Chief Financial Officer |
| Mark James Ternouth | Chief Technical Officer and Director |
| Dr. Tomasz Evan George | Chief Scientific Officer |
| Dr. Nigel McCracken M.Sc., Ph.D. | Chief Operating Officer |
| Joel Yeung | Accounting Manager |
| Clement Monteil | Head of Scientific Research and Development |
| James Wang | Head of Procurement and Sourcing |
| Lily Fu | Head of Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 16, 2024 | 6-K | Report of foreign issuer |
| Mar 15, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 22, 2024 | 6-K | Report of foreign issuer |
| Jan 22, 2024 | 424B5 | Filing |
| Jan 12, 2024 | 6-K | Report of foreign issuer |
| Dec 21, 2023 | 6-K | Report of foreign issuer |
| Dec 20, 2023 | 424B3 | Prospectus |
| Dec 20, 2023 | 6-K | Report of foreign issuer |